Established as a Delivery Technology Firm, Mirus Eyes the RNAi-as-Therapeutics Business | GenomeWeb

While Mirus, of Madison, Wis., touts itself on its website as a non-viral gene transfer company, selling tools for nucleic acid (including siRNA) transfection and labeling, the privately held company is also quietly trying to get into the business of making RNAi-based therapeutics.

But unlike most of the other RNAi-as-drugs firms, which develop siRNAs against specific targets and then try to figure out how to administer them, Mirus aims at perfecting its delivery methods first and going from there.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.